Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo

Authors：Liu, Xinyu; Li, Wenjing; Xu, Licheng; Chen, Xiaoxue; Zhao, Rui; Guo, Yan; Ge, Jingchun; Yang, Zhenming; Li, Liang; Zhang, Jiarui; Cao, Jing; Shao, Yue; Guo, Xinyue; Tian, Linli^*; Liu, Ming^*

Source：International Journal of Biochemistry and Cell Biology, 2023, 158: 106398.

DOI：10.1016/j.biocel.2023.106398

• Chidamide
• Laryngeal cancer
• Apoptosis
• Ferroptosis
• Pyroptosis

Although surgery is an important treatment for laryngeal cancer, surgery has a significant negative impact on the quality of life of patients, and many patients have poor tolerance to surgery. Therefore, alternative chemo-therapeutic drugs are an important research hotspot. Chidamide is a histone deacetylase inhibitor that selectively inhibits the expression of type I and IIb histone deacetylases (1, 2, 3 and 10). It has a significant anticancer effect on a variety of solid tumours. This study verified the inhibitory effect of chidamide on laryngeal carcinoma. We conducted a variety of cellular and animal experiments to explore how chidamide inhibits the development of laryngeal cancer. The results showed that chidamide had significant antitumour activity against laryngeal car-cinoma cells and xenografts and could induce cell apoptosis, ferroptosis and pyroptosis. This study provides a potential option for the treatment of laryngeal cancer.

• Institution
  哈尔滨医科大学; 1